MDACC Study No:2012-0696 ( NCT No: NCT01693614)
Title:An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma
Principal Investigator:Jason R. Westin
Treatment Agent:BKM120
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if BKM120 can control the
disease in patients with relapsed/refractory diffuse large B-cell lymphoma
(DLBCL), mantle cell lymphoma (MCL), or follicular lymphoma (FL). The safety of
this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:BKM120
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jason R. Westin
For Clinical Trial Enrollment:713-792-2806
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults